Éligibilité des patients aux cellules CAR-T : avis d’experts proposé par la SFGM-TC - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Bulletin du Cancer Year : 2021

Éligibilité des patients aux cellules CAR-T : avis d’experts proposé par la SFGM-TC

Denis Caillot
  • Function : Author

Abstract

The chimeric antigen receptor T-cells are a new class of anticancer treatment consisting in genetically modifying autologous or allogenic T-cells to make express a CAR directed against a membrane tumor antigen. In Europe, tisagenlecleucel (KymriahTM) has a marketing authorization for the treatment of relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia in children and young adults and of R/R diffuse large B-cell lymphoma (DLBCL). The marketing authorization for axicabtagene ciloleucel (YescartaTM) is the treatment of DLBCL and primary R/R mediastinal B-cell lymphoma. The two products are autologous T-cells directed against CD19. This collaborative work, part of a series of expert opinion-based work, aims to give practical advice to help centers in selection of patients for commercially available CAR T-cell treatment.
Embargoed file
Embargoed file
Ne sera jamais visible

Dates and versions

inserm-03349011 , version 1 (20-09-2021)

Identifiers

Cite

David Beauvais, Emmanuel Bachy, André Baruchel, Jacques-Olivier Bay, Denis Caillot, et al.. Éligibilité des patients aux cellules CAR-T : avis d’experts proposé par la SFGM-TC. Bulletin du Cancer, 2021, 108 (7-8), pp.725-729. ⟨10.1016/j.bulcan.2020.10.017⟩. ⟨inserm-03349011⟩
118 View
14 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More